Exendin-4 is being employed extensively in the therapeutic treatment of type 2 diabetes because it has a biological effect that is comparable to that of GLP-1 in vivo but has a longer half-life and a lesser tendency to degrade [36]. This evidence concerns the gene GCG and type 2 diabetes mellitus.